06:17 AM EST, 02/12/2025 (MT Newswires) -- Indivior ( INDV ) said Wednesday that the US Food and Drug Administration has delayed its decision on the marketing application for label changes to Sublocade Injection.

Indivior ( INDV ) said the FDA has no outstanding issues to address, adding that the company will provide additional updates on the approval status of the proposed label changes as needed.